Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is making strides in the clinical development of its proprietary multiple sclerosis therapy candidate, LUCID-MS, which targets demyelination and aims to protect or restore myelin integrity. The company recently reported that Phase 1 clinical studies in healthy volunteers demonstrated a favorable safety profile, with the therapy generally well tolerated, supporting advancement into patient-focused studies. In April 2026, Quantum BioPharma submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for LUCID-MS, paving the way for a planned Phase 2 clinical trial in people living with multiple sclerosis.
The company believes LUCID-MS may offer a differentiated, potentially first-in-class approach because it aims to directly address myelin loss and neurodegeneration, rather than relying solely on immune modulation. This mechanism of action could provide a new therapeutic option for patients with multiple sclerosis, a chronic autoimmune disease affecting the central nervous system. Quantum BioPharma is also strengthening operational support for the program through a planned partnership with Allucent and engagement with neurological specialists.
According to the company, LUCID-MS is a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. The advancement of this therapy is significant given the limited treatment options available that directly target myelin repair. The Phase 2 trial will evaluate the therapy's efficacy and safety in patients, building on the positive Phase 1 data.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets for the treatment of challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is focused on research and development of its lead compound, Lucid-MS. The company also retains ownership of 19.84% of Unbuzzd Wellness Inc., which markets unbuzzd, a product for alcohol moderation, and receives royalty payments from sales.
For more information on Quantum BioPharma and its pipeline, visit the company's newsroom at https://ibn.fm/QNTM. The full article discussing the clinical development can be viewed at https://ibn.fm/AUhNl.
This announcement underscores the potential of LUCID-MS to address an unmet medical need in multiple sclerosis treatment. If successful, the therapy could represent a significant advancement in neuroprotective strategies for patients.
